Current and future antiretroviral treatment options in paediatric HIV infection (Q37163343)

18 August 2017

1 reference

title

Current and future antiretroviral treatment options in paediatric HIV infection (English)

1 reference

18 August 2017

anti-retroviral agent

0 references

Anita de Rossi

6

0 references

Carlo Giaquinto

1

object named as

Carlo Giaquinto

1 reference

18 August 2017

5

Martina Penazzato

1 reference

18 August 2017

Erika Morelli

2

1 reference

18 August 2017

Federica Fregonese

3

1 reference

18 August 2017

Osvalda Rampon

4

1 reference

18 August 2017

Ruggero D'Elia

7

1 reference

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Clinical Drug Investigation

18 August 2017

1 reference

18 August 2017

28

1 reference

18 August 2017

6

1 reference

18 August 2017

375-397

1 reference

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

18 August 2017

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00044011-200828060-00005

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India

21 January 2018

1 reference

12 December 2020

Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children

1 reference

12 December 2020

Nucleoside and nucleotide reverse transcriptase inhibitors in children

1 reference

12 December 2020

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

12 December 2020

1 reference

12 December 2020

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

12 December 2020

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

1 reference

12 December 2020

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

12 December 2020

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

1 reference

12 December 2020

Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults

1 reference

12 December 2020

Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children

1 reference

12 December 2020

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

12 December 2020

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

12 December 2020

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

1 reference

12 December 2020

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

12 December 2020

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.

1 reference

12 December 2020

Nevirapine: pharmacokinetic considerations in children and pregnant women

1 reference

12 December 2020

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

12 December 2020

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy

1 reference

12 December 2020

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

12 December 2020

Tolerance of efavirenz in children.

1 reference

12 December 2020

Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?

1 reference

12 December 2020

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

12 December 2020

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

1 reference

12 December 2020

Metabolic complications of antiretroviral therapy in children

1 reference

12 December 2020

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts

1 reference

12 December 2020

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India

1 reference

12 December 2020

Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children

1 reference

12 December 2020

Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients

1 reference

12 December 2020

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

1 reference

12 December 2020

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

12 December 2020

Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults

1 reference

12 December 2020

PENTA guidelines for the use of antiretroviral therapy, 2004.

1 reference

12 December 2020

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

1 reference

12 December 2020

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

1 reference

12 December 2020

Triple nucleoside reverse transcriptase inhibitor therapy in children

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection

1 reference

12 December 2020

Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

12 December 2020

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

12 December 2020

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir

1 reference

12 December 2020

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

1 reference

12 December 2020

Lipodystrophy syndrome in human immunodeficiency virus-infected children

1 reference

12 December 2020

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

1 reference

12 December 2020

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

1 reference

12 December 2020

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data

1 reference

12 December 2020

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

1 reference

12 December 2020

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

1 reference

12 December 2020

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

1 reference

12 December 2020

Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children

1 reference

12 December 2020

A trial of three antiretroviral regimens in HIV-1-infected children

1 reference

12 December 2020

Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children.

1 reference

12 December 2020

Nevirapine use in HIV-1-infected children

1 reference

12 December 2020

Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.

1 reference

12 December 2020

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

1 reference

12 December 2020

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

12 December 2020

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.

1 reference

12 December 2020

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

1 reference

12 December 2020

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

Emerging drug targets for antiretroviral therapy

1 reference

12 December 2020

Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis

1 reference

12 December 2020

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

12 December 2020

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

1 reference

12 December 2020

[CBO guidelines 'Antiretroviral therapy in the Netherlands']

1 reference

12 December 2020

Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients

1 reference

12 December 2020

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

1 reference

12 December 2020

Paediatric HIV-1 infection

1 reference

12 December 2020

10.2165/00044011-200828060-00005

Identifiers

DOI

1 reference

18 August 2017

1 reference